Skip to main content
ALUR
NYSE Industrial Applications And Services

Allurion Technologies Receives Landmark FDA Approval for Gastric Balloon System, Unlocking U.S. Obesity Market

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
10
Price
$1.605
Mkt Cap
$13.384M
52W Low
$0.95
52W High
$4.18
52W Position info
69% above low
Off High info
62% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

ALUR sits 69% above its 52-week low of $0.95.

Summary

Allurion Technologies announced it received U.S. FDA Premarket Approval (PMA) for its Allurion Gastric Balloon System, a non-invasive weight loss solution, opening access to a large U.S. market.


Key Events · Product Development and Regulatory · ALUR

  • FDA PMA Approval Granted

    The U.S. Food and Drug Administration (FDA) granted Premarket Approval (PMA) for the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule.

  • Access to Significant U.S. Market

    The approval provides Allurion with access to approximately 80 million Americans with obesity (BMI 30-40 kg/m2) who have had unsuccessful weight loss attempts.

  • Non-Invasive Weight Loss Solution

    The Allurion Smart Capsule is swallowed in a 15-minute office visit, requiring no surgery, endoscopy, or anesthesia, and resides in the stomach for approximately four months.

  • Alternative to GLP-1s and Bariatric Surgery

    The system is positioned as a safe and effective alternative or complement to GLP-1 medications and bariatric surgery, addressing patient needs for different treatment options.


Analysis · ALUR · Industrial Applications And Services

This filing announces a pivotal FDA Premarket Approval (PMA) for Allurion's Gastric Balloon System, featuring the Smart Capsule. This approval is a transformative event for the company, granting access to the substantial U.S. market of approximately 80 million adults with obesity. The product's non-invasive nature (swallowable, no surgery, endoscopy, or anesthesia) positions it as a significant alternative or complement to existing weight loss solutions like GLP-1s and bariatric surgery. This regulatory milestone is expected to be a major catalyst for future growth and commercialization efforts, fundamentally altering the company's market potential and investment thesis.

At the time of this filing, ALUR was trading at $1.61 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $13.4M. The 52-week trading range was $0.95 to $4.18. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALUR - Latest Insights

ALUR
May 15, 2026, 4:38 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.851
Real-time Price: $0.580 info
Change: Reverse Stock Split info
Market Cap: $8.704M info
ALUR
May 08, 2026, 12:29 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.686
Real-time Price: $0.580 info
Change: Reverse Stock Split info
Market Cap: $8.704M info
ALUR
Apr 20, 2026, 8:37 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.800
Real-time Price: $0.580 info
Change: Reverse Stock Split info
Market Cap: $8.704M info
ALUR
Mar 30, 2026, 8:30 AM EDT
Filing Type: 10-K
Importance Score:
10
Price at Filing: $0.7746
Real-time Price: $0.580 info
Change: Reverse Stock Split info
Market Cap: $8.704M info
ALUR
Mar 12, 2026, 5:11 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.360
Real-time Price: $0.580 info
Change: Reverse Stock Split info
Market Cap: $8.704M info